Nanosuspension of a poorly soluble drug via microfluidization process
Provided are compositions and methods for preparation and administration of an oral nanosuspension of a poorly soluble drug with improved bioavailability. The method is optimized through microfluidization process with water soluble polymeric excipients in the absence of surfactants.
1. A stable, aqueous suspension having an enhanced bioavailability consisting of:
particles of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide having a mean particle size of less than 800 nm,
sodium lauryl sulfate (SLS) in a concentration of 0.2%, and
hydropropylmethylcellulose (HPMC) in a concentration of 0.5%,
wherein said suspension is suitable for long term storage; and
wherein said suspension has a relative exposure that is 147% of the exposure of the suspension in the absence of SLS.
2. A stable, aqueous suspension having an enhanced bioavailability consisting of:
particles of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide having a mean particle size of less than 800 nm,
vitamin E d-alpha tocopheryl polyethylene glycol 1000 succinate (E-TPGS) in a concentration of 1.5%,
PEG-8 caprylic/capric glycerides in a concentration of 1.5%, and
HPMC in a concentration of 0.5%,
wherein said suspension is suitable for long term storage; and
wherein said suspension has a relative exposure that is 129% of the exposure of the suspension in the absence of vitamin E-TPGS and PEG-8 caprylic/capric glycerides.
3. The suspension of claim 2 , wherein the D 50 analyzed by volume is 0.73 μm.
4. A stable, aqueous suspension consisting of:
particles of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide having a mean particle size of less than 800 nm,
SLS in a concentration of 0.6%, and
HPMC in a concentration of 0.5%,
wherein said suspension is suitable for long term storage and having an enhanced dissolution rate relative to the dissolution rate of the suspension in the absence of SLS.
5. The suspension of any one of claim 1 , 2 or 4 , which is stable at 5° C. for at least 6 months.
6. The suspension of any one of claim 1 , 2 or 4 , which is stable at a room temperature for at least 2 months.
7. The suspension of any one of claim 1 , 2 or 4 , which is suitable for oral administration.
8. A stable, aqueous suspension having an enhanced bioavailability consisting of:
particles of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide having a mean particle size of less than 800 nm,
vitamin E d-alpha tocopheryl polyethylene glycol 1000 succinate (E-TPGS) in a concentration of 1.5%,
PEG-8 caprylic/capric glycerides in a concentration of 1.5%, and
HPMC in a concentration of 0.5%,
wherein said suspension is suitable for long term storage; and
wherein the relative exposure of said suspension is improved by 7% relative to the exposure of the suspension in the absence of vitamin E-TPGS and PEG-8 caprylic/capric glycerides.
9. The suspension of claim 8 , wherein the D 50 analyzed by volume is 0.46 μm.
10. The suspension of claim 8 , wherein the dissolution rate increases 40 fold over 40 minutes relative to the dissolution rate of the suspension in the absence of vitamin E-TPGS and PEG-8 caprylic/capric glycerides.